WOBURN, Mass.--(BUSINESS WIRE)--OSSIO, Inc., an orthopedic fixation technology company, today announced the appointment of Gregory C. Berlet, MD, as its Chief Medical Officer. Dr. Berlet is a fellowship-trained orthopedic surgeon and nationally recognized leader in orthopedic research, education and product design.
“With his extensive strategic and clinical experience in the field of orthopedics, Dr. Berlet is uniquely positioned to help advance OSSIOfiber® technology and our ambitious portfolio plans, playing a key role in driving our business forward," said Brian Verrier, CEO, OSSIO. “As Chief Medical Officer, he will provide critical clinical expertise, insight and guidance as we continue to scale our high-growth business for the future and elevate bio-integrative OSSIOfiber® as the new standard of care in the field of orthopedic fixation."
In this new role, Dr. Berlet will provide leadership and direction in accelerating OSSIO’s clinical programs and the progress of its OSSIOfiber® Intelligent Bone Regeneration Technology product pipeline as the company works to pursue multiple applications in all major segments of orthopedics. Specifically, he will guide and support OSSIO’s clinical trial strategy, design and execution; new product development; medical and regulatory affairs; clinical education; and peer-to-peer customer relations initiatives across podiatric and orthopedic specialties. Dr. Berlet will report to Brian Verrier and serve on the OSSIO senior leadership team, while continuing his role as a practicing orthopedic surgeon and active member and faculty of the major orthopedic societies.
“I am excited to join OSSIO at such an integral stage of growth and evolution for the company as we work to transform the orthopedic fixation market,” said Dr. Berlet. “As an early adopter of OSSIOfiber® bio-integrative implants in my own surgical practice, I can attest to the technology’s unique clinical benefits of providing immediate stable fixation that physiologically adapts with the bone during the healing process, as well as the significant patient benefit of not having to live with a permanent metal implant and thus avoiding all the post-operative complications that often accompany that hardware. Together with our experienced leadership team, I look forward to helping the company drive strong adoption of our technology to the broad orthopedic and podiatric sectors, accelerate the development of our robust product pipeline and deliver innovative patient care.”
Dr. Berlet, a founding partner of the Orthopedic Foot & Ankle Center (OFA) in Columbus, Ohio, brings over two decades of experience as an orthopedic surgeon with subspecialty fellowship training in foot and ankle surgery and sports medicine. Throughout his distinguished career, he has been on the forefront of foot & ankle education, having clinically trained 54 orthopedic and podiatric fellows through OFA’s dynamic multi-disciplinary practice. A firm believer that quality of education and training make a significant difference in treatment outcomes, Dr. Berlet regularly lectures at national and international medical conferences, is a past member of the American Academy of Orthopaedic Surgery’s (AAOS) Council on Education, past chair of Education for the American Orthopaedic Foot & Ankle Society (AOFAS), past board member of the AAOS Continuing Medical Education Committee and Chief of Foot and Ankle at The Ohio State University. He is also active on the research front, having authored more than 150 peer-reviewed scientific publications and partnered with industry leaders on the design and development of numerous orthopedic implants as a means to increase positive surgical outcomes.
About OSSIOfiber® Intelligent Bone Regeneration Technology
Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber® Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone that leaves nothing permanent behind. OSSIOfiber® is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. OSSIOfiber® implants utilize existing reimbursement and surgical techniques. The OSSIOfiber® Hammertoe Fixation System, the OSSIOfiber® Bone Pin Family (which includes the OSSIOfiber® Trimmable Fixation Nail System) and the OSSIOfiber® Compression Screw Portfolio are cleared for use in the United States for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts in the presence of appropriate additional immobilization.
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multi-billion-dollar global orthopedic fixation market with its OSSIOfiber® Intelligent Bone Regeneration Technology. OSSIO’s development headquarters is located in Caesarea, Israel, and its commercial headquarters is in Woburn, Massachusetts, USA. For more information on the company visit www.ossio.io.